CLColgate-Palmolive

$88.27+10% 1Y

$88.27

$74.0652 weeks$98.53

CL in its own filings

Nothing in CL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

450

Events found in the filings · across 3,949 filings · the record starts in 1994

Hard flags: none
Hard flags
Most recent filing: Jul 31, 2026
Most recent filing · Form 10-Q
Record starts: Mar 25, 1994
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 30, 2026
Change in certifying accountant2 occurrences: 2007-06-08
Security removed from listing or deregistered6 occurrences · usually a matured note or preferred class, not the common shares: 2026-03-06
SEC comment-letter activity52 occurrences: 2017-05-10

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

May 1, 2026As previously disclosed, on July 31, 2025, the Company’s Board of Directors (“Board”) approved a three-year productivity program to drive future growth and support the Company’s 2030 strategy (the “Strategic Growth and Productivity Program”)Earnings release · Form 8-K
Apr 9, 2026Jennifer M. Daniels, who has served as Chief Legal Officer and Secretary of Colgate-Palmolive Company (the “Company”) since 2014, has communicated to the Company her intention to retire from the Company in 2026.Director or officer change · Form 8-K
Mar 17, 2026As part of the previously announced Strategic Growth and Productivity Program, to further optimize and leverage the operating scale and drive growth within the Europe and Africa/Eurasia regions, effective for the quarter ending March 31, 2026, Colgate-Palmolive Company (the “Company”) has realigned its reportable …Other event · Form 8-K
Mar 12, 2026On March 12, 2026, the Board of Directors (the “Board”) of Colgate-Palmolive Company (“Colgate-Palmolive”) elected Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company (“Bristol Myers Squibb”), to the Colgate-Palmolive Board, effective March 15, 2026.Director or officer change · Form 8-K
Nov 10, 2025On November 3, 2025, Colgate-Palmolive Company (the “Company”) executed an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC and Banco Bilbao Vizcaya Argentaria, S.A., as representatives of the several underwriters named therein (the “Underwriters”) with regard to the issuance and sale by …Other event · Form 8-K
Oct 31, 2025As previously disclosed, on July 31, 2025, the Company’s Board of Directors approved a new three-year productivity program to drive future growth and support the Company’s 2030 strategy (the “Strategic Growth and Productivity Program”)Earnings release · Form 8-K